文献速递流行病学与生物统计临床试验与 GCP

阿片暴露新生儿戒断结局报告的系统综述

Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review.
PubMed 文献 · Trials · 2020-03-12

最常见结局为药物治疗持续时间(68%,N=32)、住院时间(66%,N=31)和戒断症状(51%,N=24),但结局定义和测量时间异质,且无研究纳入父母参与结局选择。结论认为结局选择不一致阻碍证据合成,亟需制定核心结局集。

要点

  • 药物治疗持续时间、住院时间和戒断症状是报告最多的结局。
  • 结局定义和测量时间异质,妨碍证据合成。
  • 无研究纳入父母或既往患者参与结局选择。

核心结论

  • 现有文献中用于管理新生儿阿片戒断的药物和非药物干预措施的主要和次要结局的选择与定义不一致。
  • 无研究在结局选择过程中纳入父母。
  • 这些发现阻碍了证据合成以生成有临床意义的实践指南,制定特定的核心结局集是必要的。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE和Cochrane Central数据库,纳入2007年7月至2017年7月间报告新生儿戒断综合征干预结局的原始研究(随机对照试验、临床试验、病例对照研究、非对照试验、观察性队列研究、临床实践指南和病例报告)。
  • 由两名独立评价者提取所有主要和次要新生儿结局,并归入OMERACT核心领域。

主要发现

  • 最常报告的结局为药物治疗持续时间(68%的研究,N=32)、住院时间(66%的研究,N=31)和戒断症状(51%的研究,N=24)。
  • 结局报告次数与文章数之间的差异源于复合结局的使用。
  • 常报告的结局定义异质或未由研究定义,且在不同时间测量。
  • 迄今文献报告的结局主要归入病理生理表现或资源使用核心领域。

临床怎么用

  • 临床研究者应关注结局定义的标准化,以促进证据合成和指南制定。
  • 未来研究应纳入父母参与结局选择,以反映家庭关注的重点。

局限性

  • 检索时间范围为2007年7月至2017年7月,可能未涵盖更新文献。
  • 仅纳入特定类型的研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neonatal withdrawal secondary to in utero opioid exposure is a growing global concern stressing the psychosocial well-being of affected families and scarce hospital resources. In the ongoing search for the most effective treatment, randomized controlled trials are indispensable. Consistent outcome selection and measurement across randomized controlled trials enables synthesis of results, fostering the translation of research into practice. Currently, there is no core outcome set to standardize outcome selection, definition and reporting. This study identifies the outcomes currently reported in the literature for neonates experiencing withdrawal following opioid exposure during pregnancy. METHODS: A comprehensive literature search of MEDLINE, EMBASE and Cochrane Central was conducted to identify all primary research studies (randomized controlled trials, clinical trials, case-controlled studies, uncontrolled trials, observational cohort studies, clinical practice guidelines and case reports) reporting outcomes for interventions used to manage neonatal abstinence syndrome between July 2007 and July 2017. All "primary" and "secondary" neonatal outcomes were extracted by two independent reviewers and were assigned to one of OMERACT's core areas of "pathophysiological manifestation", "life impact", "resource use", "adverse events", or "death". RESULTS: Forty-seven primary research articles reporting 107 "primary" and 127 "secondary" outcomes were included. The most frequently reported outcomes were "duration of pharmacotherapy" (68% of studies, N = 32), "duration of hospital stay" (66% of studies, N = 31) and "withdrawal symptoms" (51% of studies, N = 24). The discrepancy between the number of times an outcome was reported and the number of articles was secondary to the use of composite outcomes. Frequently reported outcomes had heterogeneous definitions or were not defined by the study and were measured at different times. Outcomes reported in the literature to date were mainly assigned to the core areas "pathophysiologic manifestations" or "resource use". No articles reported included parent or former patient involvement in outcome selections. CONCLUSIONS: Inconsistent selection and definition of primary and secondary outcomes exists in the present literature of pharmacologic and nonpharmacologic interventions for managing opioid withdrawal in neonates. No studies involved parents in the process of outcome selection. These findings hinder evidence synthesis to generate clinically meaningful practice guidelines. The development of a specific core outcome set is imperative.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Shan F, MacVicar S, Allegaert K, et al. Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review. Trials. 2020. PMID: 32164782. doi:10.1186/s13063-020-4183-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。